Mode
Text Size
Log in / Sign up
Phase 3 Completed N=183 Randomized Double-blind Treatment

Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Source: ClinicalTrials.gov NCT01657253 ↗
Enrolled (actual)
183
Serious AEs
0.5%
Results posted
Dec 2017
Primary outcomePrimary: Ocular Surface Disease Index (OSDI©) Questionnaire — 19.3; 19.3; 7.3; 7.9 points
◆ Published Evidence
Established
25citations · ~3 / year
Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial.
BMC ophthalmology · 2016 · Open access · Likely link

Summary

The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-148 in the ocular surface of patients with mild to moderate dry eye compared with ophthalmic solution Systane®

Linked Publications

  • Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial.
    BMC ophthalmology · 2016 · 25 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Ocular Surface Disease Index (OSDI©) Questionnaire
19.3; 19.3; 7.3; 7.9
SECONDARY
Schirmer Test
6.4; 6.5; 11.0; 10.5
SECONDARY
Tear Film Break up Time
5.5; 5.2; 7.4; 7.4

Eligibility Criteria

Inclusion Criteria

  • Mild to moderate dry eye patients based on the Report of International Dry Eye Workshop (DEWS)
  • OSDI score between 12 and 45
  • Provided informed consent

Exclusion Criteria

  • Patients with one blind eye
  • Visual acuity of 20/100 or worst in any eye
  • Patients with any active ocular disease that would interfere with study interpretation
  • Patients in treatment with any medication that could interfere with the study, contraindication of any medication used in the protocol
  • Patients with history of hypersensitivity or contraindication for any drug used in the study
  • Contact lens users
  • Pregnant patients, at risk of pregnancy or breastfeeding
  • Patients without birth control treatment
  • Patients who had participated in any clinical trial in the last 90 days
  • Legal or mentally disabled patients who could not give informed consent
  • Patients who do not provide informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01657253) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search